177lu-dota-jr11
mAbexperimentalImaging agent
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 13, 2015 (NCT02609737)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Disialoganglioside GD2Immunity, passive
Disialoganglioside GD2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 68-Gallium
Oral
No
Parenteral
No
Topical
No
Also known as
- 177lu-dota-jr11
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04997317 | Early Phase 1 (Phase 1) | Apr 21, 2021 | Swiss Cancer League, University of Basel |
| NCT02609737 | N/A | Nov 13, 2015 | Cornell University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Swiss Cancer League | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Basel | Academic/Hospital | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1